Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ahead of its rescheduled February meeting being held on April 15-16. Information provided within the respiratory syncytial virus older adult slides indicates the majority of the working group recommend RSV vaccine intervention to those aged 50-59 years at increased risk, the analyst tells investors in a research note. Goldman believes the slides suggest the committee will likely vote to expand its recommended population for GSK‘s (GSK) Arexvy to those aged 50-59. This would represent a “positive surprise” for GSK, contends the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK CEO says the company can navigate through the tariffs, Bloomberg says
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- GSK Pharma call volume above normal and directionally bullish
- GSK pushes UK government to give more access to health data, Bloomberg says
- RFK Jr. plans to cut 10,000 jobs in HHS, WSJ reports